| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Dec 3, 2025 | Dec 4, 2025 | Editas Medicine, Inc. | CEO | Sell | 46.3 | -5,603 | -2.04% | ✗ | $12.1K |
| Sep 3, 2025 | Sep 4, 2025 | Editas Medicine, Inc. | CEO | Sell | 46.3 | -5,592 | -2.00% | ✗ | $14.5K |
| Jun 3, 2025 | Jun 4, 2025 | Editas Medicine, Inc. | CEO | Sell | 46.3 | -15,192 | -5.14% | ✗ | $26.2K |
| Mar 4, 2025 | Mar 5, 2025 | Editas Medicine, Inc. | CEO | Sell | 46.3 | -16,632 | -5.33% | ✗ | $28.5K |
| Dec 3, 2024 | Dec 5, 2024 | Editas Medicine, Inc. | CEO | Sell | 50.0 | -1,618 | -0.52% | ✗ | $3.4K |
| Sep 4, 2024 | Sep 6, 2024 | Editas Medicine, Inc. | CEO | Sell | 52.5 | -1,555 | -0.49% | ✗ | $5.3K |
| Jun 4, 2024 | Jun 6, 2024 | Editas Medicine, Inc. | CEO | Sell | 42.5 | -12,191 | -3.72% | ✗ | $67K |
| Mar 2, 2024 | Mar 5, 2024 | Editas Medicine, Inc. | CEO | Sell | 97.5 | +197,301 | 151.57% | ✗ | $732.9K |
| Jun 5, 2023 | Jun 7, 2023 | Editas Medicine, Inc. | CEO | Sell | 42.5 | -6,486 | -4.75% | ✗ | $61.6K |
| Feb 28, 2021 | Mar 10, 2021 | Sarepta Therapeutics, Inc. | EVP, R&D & CMO | Sell | 91.3 | +14,476 | 102.89% | ✗ | $45.6K |
| May 23, 2019 | May 24, 2019 | Sarepta Therapeutics, Inc. | EVP, R&D & CMO | Sell | 20.0 | -4,630 | -38.58% | ✗ | $552.4K |